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For the first time estrogen DNA-adducts were identified in DNA human breast tumor tissue
using nano-LC coupled to nano-Electrospray Tandem Mass Spectrometry. Normal breast
tissue was analyzed analogously. The data obtained in the five breast tumor and five adjacent
normal tissue samples were compared qualitatively, but no straightforward difference was
observed. Prior to LC-MS analysis the DNA was enzymatically hydrolyzed to a nucleoside
pool. The DNA-hydrolysates were directly injected onto a column switching system developed
for on-line sample clean-up and subsequent analysis of the DNA-adducts. In four patients
using Premarin, DNA-adducts of 4-hydroxy-equilenin (4OHEN) were detected. All except
three samples contained DNA-adducts from 4-hydroxy-estradiol or 4-hydroxy-estrone. Also
DNA isolated from eight alcohol fixed and paraffin embedded breast tumor tissue showed the
presence of different estrogen DNA-adducts. Worthwhile mentioning is the presence of
adducts responding to m/z 570  m/z 454 transition. This is a well-known SRM-transition
indicative for the presence of the 2'-deoxyguanosine (dGuo) adduct of Benzo[a]pyrene. (J Am
Soc Mass Spectrom 2003, 14, 482–491) © 2003 American Society for Mass Spectrometry
Hormone treatment is widespread for women ofall ages. In the United States, for instance, 30%of post-menopausal women use hormone ee-
placement therapy (HRT) [1], e.g., Premarin. Studies in
which the development of breast and endometrial can-
cer was associated with estrogen therapy [2–6] were
supported by a more recent follow-up study in which it
was demonstrated that post-menopausal women have
an increased risk of breast cancer when using estrogens,
especially in combination with progestin [7]. In animals,
too, a relationship between the administration of estro-
gens and the development of cancer was shown [8].
The carcinogenic properties of estrogens are ex-
plained by direct stimulation of cell proliferation via
estrogen receptor mediated mechanisms [9, 10] and by
mechanisms based on metabolic activation [11–14],
leading to DNA damage such as oxidative damage
[15–18] and the formation of DNA-adducts [19–28],
which can cause mutations and induce cancer [29].
The latter pathways are the result of metabolic
activation of estrogens by the cytochrome P-450 system
leading to 2- and 4-hydroxy derivatives. The 2-hydroxy
estrogens are excreted in the urine as a result of their
fast transformation to water-soluble compounds [13,
14]. The 4-hydroxy form, however, has a longer half-life
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in the body and is further oxidized to the o-quinone-
estrogen which can alkylate DNA [19–28]. In this re-
spect, equilenin is noteworthy because of its fast trans-
formation to the 4-hydroxy and quinone metabolites
(Scheme 1) [17, 18, 30].
The aim of our research is to elaborate LC-MS
technology to such an extent that it can be used in the
analysis of DNA-adducts present in humans, where a
limited amount of sample is one of the limiting factors
and sensitivity is one of the main issues. In this com-
munication we wish to present our first, though prelim-
inary results on the analysis of estrogen DNA-adducts
isolated from small amounts of surgically removed
breast tumor tissue by means of nano-LC/nano-electro-
spray tandem mass spectrometry in combination with
column switching 2-dimensional (2-D)LC/nano ES
MS/MS).
Following the report of D. Li et al. [31, 32] of the
detection of aromatic DNA-adducts of Benzo[a]pyrene
in adjacent breast tumor tissue, we also decided to
search for Benzo[a]pyrene adducts of 2'-deox-
yguanosine (dGuo) in both malignant and non-malig-
nant tissue. Generally, DNA-adducts were detected in
small amounts of DNA (38 g or less).
Experimental
Products and Materials
The necessary enzymes Proteinase K, Nuclease P1,
Phosphodiesterase I from Croltalus adamanteus
venom, alkaline phosphatase type III from Esherichia
Coli, and water saturated buffered phenol were pur-
chased from Sigma (Bornem, Belgium). Absolute etha-
nol was purchased from Riedel-de-Hae¨n (Bornem, Bel-
gium) and Tris-buffer from Fluka (Bornem, Belgium).
All other chemicals used for DNA isolation or hydro-
lysis and HPLC analysis where purchased from Acros
Organics (Eupen, Belgium).
Flow rates for nano-columns and pre-columns were
delivered by a splitless CapLC system (Waters, Brus-
sels, Belgium). This ternary system was used in a binary
mode (A and B reservoirs were used to deliver the nano
flow rates, C reservoir was used to load the pre-
column). The CapLC system was connected to a FA-
MOS micro-injection system.
Nano-LC columns were purchased from LC-Pack-
ings (Amsterdam, The Netherlands). Two different sta-
tionary phases were used: Hypersyl C18 BDS, 3 m
particles (75 m i.d.  150 mm) and Hypersyl C8 BDS,
5m particles (75 m i.d.  150 mm). Another analytical
column used in many experiments was a picofrit col-
umn (75m i.d.  100 mm; New Objective, Cambridge,
MA). The pre-column was a 300 m i.d.  5mm column
packed with C18P3 as stationary phase (LC-Packings,
Amsterdam, The Netherlands).
As detector, a Quattro II tandem mass spectrometer
(Micromass, Manchester, UK) was used. The instru-
ment was equipped with a Z-spray source and an
electrospray NanoFlow probe. If the Picofrit column
was used a Picosprayer (Micromass, Manchester, UK)
was installed.
Preparation of Standards
Equilenin metabolite and its adducts were prepared
according to the method Shen et al. [19], also described
by us in an earlier paper [33]. Aliquots of 1 mL of
sample were dried under reduced pressure and dis-
solved in 1 mL of methanol. An equal volume (10 L) of
each of the reaction mixtures was mixed together with
1 mL of water to get a solution of dGuo, 2'-deoxyade-
nosine (dAdo), and 2'-deoxycytidine (dCyd)-4OHEN
adducts. This mixture was diluted 1000 times with
water and after filtration, used for injection on the
column switching system.
Two mg of Calf Thymus DNA dissolved in 1.5 mL of
phosphate buffer (25 mM, pH 7,4), was treated with 1.5
mg of 4OHEN (in 500 L methanol). After 4 h of
reacting at 37 °C the DNA was precipitated with 4 mL
of ice-cold 70% ethanol. After centrifugation, the super-
natants could be removed and the DNA was ready for
enzymatic hydrolysis.
Standards of 4-hydroxy-17--ethynyl-estradiol with
dGuo, dAdo, and dCyd as well as 4-hydroxy-estrone
with dGuo and dAdo were made by the procedure
described by Cavalieri et al. [26]. Briefly, the 3,4-estro-
gen quinones were made from the 4-hydroxy analogs
using activated manganese dioxide. The quinone was
then reacted with the 2'-deoxynucleosides at 37 °C for
5 h in an acetic acid/water (50/50) environment. These
samples were dried under reduced pressure and redis-
solved in methanol and diluted 1000 times with water
before injection.
DNA Isolation from Tissue
Breast tumor tissue and normal tissue located adjacent
to the tumor tissue were obtained for DNA adduct
measurements from biopsies of five patients. The origin
of the samples (patients) is summarized in Table 2. In
Patient 1 the tumor was a moderately defined ductal
adenocarcinoma, in Patient 2 the tumor was a well
defined ductal adenocarcinoma, Patient 3 had an intra-
cystic papillary carcinoma, Patient 4 had a poorly
defined ductal adenocarcinoma, and from Patient 5 the
type of tumor was unknown. From each sample at least
0.20 cm3 was obtained. Larger samples were cut into
pieces of 0.20 cm3 prior to enzymatic digestion. With
regard to sample preparation both malignant and
healthy tissues were treated analogously. To each sam-
ple 1 mL of digestion buffer, 50 L of DNA-ase and
RNA-ase free sodium dodecyl sulfate (10% solution)
and 0.15 mg proteinase K (dissolved in water) was
added. This mixture was put in an oven at 50 °C
overnight and was meanwhile gently shaken. The di-
gestion buffer consisted of 100 mM sodium chloride, 25
mM EDTA, and 10 mM Tris/HCl buffered at pH 8. The
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overnight digested sample was extracted with the same
volume of extraction mixture [50% of water saturated
phenol (pH 7.9), 25% of chloroform and 25% 3-methyl-
1-butanol] and centrifuged for 10 min at 12,000 rpm.
The upper aqueous layer containing the DNA and was
collected. A 4 M sodium chloride solution (1/10 of the
digestion buffer volume) was added to the DNA solu-
tion and the DNA was precipitated with ice-cold etha-
nol (at least 2 volumes). DNA samples were centrifuged
for 30 min at 12,000 rpm and the liquid was removed
from the precipitated DNA pellet. DNA pellets were
washed with ice-cold 70% ethanol and centrifuged
again. The wash liquid was removed with a small
pipette and the pellet was further dried under a nitro-
gen-flow.
Eight breast tumor biopsies (Patients 6–13 in Table 2)
were processed from alcohol fixed paraffin embedded
material. The tumors were all invasive ductal carcino-
mas. 30–60 sections of 10 m thickness were used of
biopsies from 1 to 2 cm2 diameter (0.5 cm3 of tumor
tissue). No DNA could be isolated from formaldehyde-
fixed tissue. Deparafination was done by shaking the
30–60 sections in 1 mL of toluene (37 °C, 15 min),
followed by centrifugation and removal of toluene. This
action was repeated. Then, the pellet was shaken twice
in 1 mL of isopropanol, centrifuged and the isopropanol
was removed. The pellet was further dried under
nitrogen flow. Further digestion and isolation of DNA
was carried out in the same way the fresh tissue was
treated.
DNA quantification was by UV spectroscopy at 260
nm. If the A260/A280 ratio was between 1.6 and 1.9, the
DNA was considered to be pure.
The DNA extracted from 0.5 cm3 of breast tumor
tissue was in most cases between 350 and 900 g, for
normal tissue adjacent to the tumor tissue the yield was
lower (60–100 g).
Enzymatic DNA Hydrolysis
DNA hydrolysis was done according to the method of
P. Crain [34]. 250 g of DNA was dissolved in 500 L of
1 mM Tris/HCl (pH 7.4). The DNA was denatured by
heating for 3 min at 100 °C and rapidly chilled in ice
water slush. Then 1/10 volume of 0.1 M ammonium
acetate (pH 5.3) and 20 units nuclease P1 (dissolved in
0.05 M ammonium acetate pH 5.3) was added and the
mixture was kept at 45 °C. After 2 h, 1/10 volume of
fresh ammonium bicarbonate (1 M, pH  7.8) was
added and 0.02 units of venom phosphodiesterase. This
Table 2. Type of tissue with corresponding adducts
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1. tumor 100                 unknown
1. normal 100                 unknown
2. tumor 100                 estradiol derivatives
2. normal 100                 estradiol derivatives
3. tumor 100                 unknown
3. normal 100                 unknown
4. tumor 20               Oc  Premarin
4. normal 20               O  Premarin
5. tumor 20               O  Premarin
5. normal 20               O  Premarin
6. tumor 100                 No HSTd
7. tumor 100                 Premarin
8. tumor 100                 Premarin
9. tumor 100                 Probably no HST
10. tumor 100                 no HST
11. tumor 100                 no HST
12. tumor 100                 no HST
13. tumor 100                 Premarin
aNumbering refers to the origin of the sample, i.e., patient.
b100 L injection volume is 38 g DNA, 20 L is 7.6 g.
cO  not tested on the compound.
dHST  Hormone substitute therapy.
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mixture was put in an oven for 2 h at 37 °C and
meanwhile gently shaken. Then 5 units of alkaline
phosphatase were added and the mixture was kept for
1 h at 37 °C. The procedure resulted in a complete
digestion of the DNA to 2'-deoxynucleosides. After
ultrafiltration this solution was used immediately for
analysis by LC/MS.
In order to check the validity of this enzymatic
procedure, calf-thymus DNA was incubated with
4OHEN for 4 h and was enzymatically hydrolyzed
according to the same procedure as described above.
The completion of the reaction was checked by
HPLC-UV and subsequent LC-MS analysis of this calf-
thymus DNA hydrolysate showed the presence of the
12 4OHEN-2'-deoxynucleoside adducts (4 isomeric ad-
ducts each for dAdo, dCyd, and dGuo).
HPLC Conditions
Aliquots of 20 to 100 L were injected on a pre-column
(300 m  5mm) in 10 mM ammonium acetate as mobile
phase to flush the unmodified nucleosides to the waste.
The flow rate over the pre-column was 7.5–10 L/min.
After 5 to 12 min, depending on the injection volume (5
min for 20 L, 7.5 L/min and 12 min for 100 L, 10
L/min), the pre-column was back-flushed to elute the
DNA-adducts to the analytical nano-HPLC column.
The flow rate over the analytical column was 300
nl/min (split-less).
The initial conditions were 10 mM ammonium ace-
tate/methanol (13/87) for 22 min. Then a linear gradi-
ent was started going to 60% methanol in 15 min. These
conditions were kept for another 3 min. Then, the
column was flushed with 90% methanol.
When the picofrit column was used the aforemen-
tioned method was modified. The C18 pre-column was
now loaded with 0.2% acetic acid containing 2% meth-
anol. DNA-adducts were directed to the analytical
picofrit column by a forward flush. The separation on
the picofrit column was done using 0.2% of acetic acid
and methanol (80/20) for 20 min. Then a linear gradient
was started going to 60% of methanol in 15 min. This
composition was kept constant for another 3 min. After
this the column was flushed with 90% methanol to
remove all impurities. Importantly, the column was
equilibrated for 1 h before each injection and that
between each sample one or more blank samples of
water were injected.
Mass Spectrometric Conditions
The nano-HPLC column was directly coupled to the
nano-electrospray probe (Micromass, Manchester, UK).
All analyses were done under ()ES conditions in SRM
mode following the [MH]  [BH2]
 transition. The
different SRM transitions are summarized in Table 1.
Dwell time, cone voltage (CV), and collision energy
(CE), were the same for each SRM function and were set
at 0.1 s, 40 V, and 15 eV, respectively. The ionization
voltage was 3.50–3.65 kV, the collision gas was argon at
3.6  103 mbar, and the source temperature was kept at
45 °C. The flow rate of the drying gas was 30 L/hour
and the cone gas flow rate was set at 10 L/hour.
Results and Discussion
The collection of quantitative and qualitative informa-
tion on DNA-adducts present in DNA from “in vivo”
sources is important in order to get a better insight on
tumor formation. Most importantly, data on adducts
found in human DNA are extremely valuable because
of their impact on human health. LC-MS has often been
mentioned as a powerful method in this area because
compared to 32P-post labeling, it should be capable of
identifying DNA-adducts regardless of the presence of
reference material. Up to the present time, many of the
literature data describe the results of in vitro experi-
ments in which the issue of sensitivity is of minor
importance. However, more data from in vivo experi-
ments is becoming available on the detection of adducts
found in animals treated with xenobiotics under con-
trolled circumstances [22–25, 29, 35]. In some of these
studies LC MS was used [36–41] as the method of
choice.
LC-MS Analysis of Standard DNA Adducts
The coupling of a miniaturized 2-DLC system to tan-
dem mass spectrometry is a powerful approach en-
abling the analysis of low quantities of DNA-adducts
present in a matrix of mainly unmodified 2'-de-
oxynucleosides [33, 42–49].
The performance of the nano-LC-ES MS/MS system
was studied with in vitro prepared DNA-adducts of
4OHEN with dGuo, dAdo, and dCyd (Scheme 2c). As
shown, all these 2'-deoxynucleosides gave four isomeric
DNA-adducts [17, 18, 33] numbered 1 to 4 according to
their elution order.
In vitro prepared reaction mixtures with 17--ethy-
Table 1. SRM-transitions
[MH]  m/z Component
512  396 Estrone–dCyd–adduct
514  398 Estradiol–dCyd–adduct
524  408 Equilenin–dCyd–adduct
527  411 Estrone–Thy–adduct
529  413 Estradiol–Thy–adduct
536  420 Estrone–dAdo–adduct
538  422 Estradiol–dAdo–adduct
Ethynyl-estradiol–dCyd–adduct
548  432 Equilenin–dAdo–adduct
552  436 Estrone–dGuo–adduct
553  437 Ethynyl-estradiol–Thy–adduct
554  438 Estradiol–dGuo–adduct
562  446 Ethynyl-estradiol–dAdo–adduct
564  448 Equilenin–dGuo–adduct
570  454 Benzo-[a]-pyrene–dGuo–adduct
578  462 Ethynyl-estradiol–dGuo–adduct
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nylestradiol-3,4-quinone gave different adducts
(Scheme 2a): Two dGuo adducts, two dAdo adduct
isomers, and three 2'-deoxycytidine adducts. Also for
4-hydroxy-estrone adducts could be found in “in vitro”
prepared mixtures: Two dGuo adducts and only one
major dAdo adduct (Scheme 2b). Analogously to the
4OHEN adducts also here the different isomers were
numbered according to the elution order.
All DNA-hydrolysates were injected on a miniatur-
ized 2-DLC MS/MS system in order to discard the
major fraction, i.e., unmodified 2'-deoxynucleosides,
prior to analysis of the adducts.
The DNA-adducts were pre-concentrated on the
pre-column and were back-flushed after 5 to 12 min to
the nano-LC-column for separation. Because of the
more lipophylic character of the adducts it was possible
to use high volume injections on the pre-column. It was
shown that the injection of 10 L of a 1.75  1010 M
solution of dG4 [33] gave the same results as the
injection of 100 L of a 1.75  1011 solution, i.e., all
adducts were retained on the pre-column without any
loss to the waste. Four aliquots of 100 L of a 1.75 
1011 solution were injected. The relative standard
deviation of the retention time was 2% and the standard
deviation of the peak area was 24%.
All the isomers formed between the different 2'-
deoxynucleoside and each of the estrogens were iso-
baric. However, analysis of the low energy collision
activated dissociation (CAD)-spectra of the [MH] did
not allow us to elucidate the exact structures, i.e., the
exact alkylation site at the heterocyclic moiety. Some of
these product ion spectra were even identical. These are
probably positional isomers formed by reaction at a
different site of the heterocyclic moiety. In contrast to
the 4OHEN-adducts, in this case no diasteromers can be
formed.
Chromatographic Behavior
Depending on the different gradient conditions and the
different solvent systems, the retention times changed
slightly for all reference compounds. Reference com-
pounds were available for most of the adducts except
for the adduct of 4-hydroxy-estradiol. The adduct with
the smallest k'-value was dG1 (tr  24.5 min for the
system with acetic acid and a picofrit column). The last
eluting adduct (highest k'-value) was the dGuo-4-hy-
droxy-17--ethynylestradiol adduct (tr  41.6 min for
the system with acetic acid and a picofrit column). All
Scheme 1. Structure of equilenin, 4-hydroxy-equilenin, and
3,4-equilenin-o-quinone.
Scheme 2. (a) 17-ethynylestradiol-2'-deoxyadenosine adduct. (b) Estrone-2'-deoxyguanosine ad-
duct. (c) Equilenin-2'-deoxyguanosine adduct. (d) Estradiol-2'-deoxyguanosine adduct.
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the in vitro synthesized adducts of 4OHEN (4 dAdo
isomers, 4 dCyd-isomers, and 4 dGuo-isomers), 4-hy-
droxy-estrone (1 dAdo isomers and 2 dGuo-isomers)
and 4-hydroxy-17--ethynylestradiol (2 dAdo isomers,
3 dCyd-isomers, and 2 dGuo-isomers), 22 in total, elute
within this time frame. Due to the highly apolar char-
acter of estrone, estradiol, ethynylestradiol, and equile-
nin, all adducts of these estrogen are likely to behave
similar on a reversed phase LC system. Therefore they
are expected to all elute in the same time frame, fixed by
the two mentioned reference adducts (dG1: 24.5 min
and dGuo-4-hydroxy-17--ethynylestradiol adduct:
41.6 min). Benz[a]pyrene adducts are probably even
more apolar than the estrogen adducts and therefore
are expected to have a higher retention time compared
to the estrogen-adducts.
Although different gradients were used, the reten-
tion of the compounds varied only slightly (e.g., dG1:
from 24.5 to 19.0 min and dG4: from 47.4 40.9 min).
Mass Spectrometric Detection
Because it was expected that DNA-adducts in both
malignant and non-malignant tissue would be present
in very low quantities, the DNA hydrolysates were
analyzed under ()ES using the specific [MH] 
[BH2]
 SRM transition (see Table 1). These transitions
were selected from the low energy CAD product ion
scans of the different standards. The typical SRM tran-
sition for the benzo[a]pyrene adduct was found in the
literature [50]. The [MH]  [BH2]
 transition is a well
known fragmentation pattern for (2'-deoxy)nucleosides
because of the preferred cleavage of the anomeric bond
[26, 27, 33, 43, 44, 51, 52]. For a CV of 40 V and a CE of
15 eV the loss of the 2'-deoxyribofuranosyl group from
the protonated molecule [MH] was the main fragmen-
tation pattern for all our reference compounds. The
above mentioned energy settings were optimized for
the 4OHEN adducts and kept constant during the
LC-MS run. If the S/N ratio was higher than two in a
certain SRM channel, the adduct with the correspond-
ing SRM transition was stated as present. (As described
by us in an earlier paper [33], the sensitivity of the
method was investigated: 197 fg of a dG4 adduct could
still be detected under SRM conditions with S/N of 8.4.)
Analysis of DNA-Hydrolysates from DNA Isolated
from Breast Tissue
A total of 18 samples was analyzed: 5 malignant breast
tissue samples, 5 samples of adjacent tumor tissue, and
8 alcohol fixed and paraffin embedded malignant breast
tumor tissue samples. Fifteen out of these eighteen
DNA samples showed a SRM respons for estrogen
adducts (Table 2) and almost every DNA sample
showed the presence of a dGuo adduct of 4-hydroxy-
estradiol (Figure 1, Scheme 2d) and 4-hydroxy-es-
trone (4-hydroxy-estrone adduct 1) respectively at lev-
els practically up to five times the detection limit [33].
Both adducts have very comparable retention times in
the middle of the earlier mentioned retention time
frame. Furthermore, the identified dGuo-4-hydroxy-
estrone adduct has the same retention time as the
corresponding standard. Since estradiol and estrone are
both endogenous estrogens the presence of the corre-
sponding adducts was not surprising.
Also, endogenous estrogens adducts with thymidine
(sample 1, 2, 7–11) and dAdo (samples 11 and 13, Figure
2) were found. Noteworthy was that adducts were
found in the DNA of both normal and malignant tissue
but no straightforward differences could be noticed. An
interesting result of the nano-LC MS/MS analysis was
the response for SRM transition typical for the adducts
of exogenous administrated estrogens like equilenin
and 17--ethynylestradiol. 4OHEN adducts with dAdo
(patients 1, 4, Figure 3), dGuo (patient 13, Figure 4) and
dCyd (patients 3, 6) were detected at retention times at
which the in vitro made 4OHEN standards were elut-
ing. More specific dA3, dG4 and dC3 or dC4 were
detected. Since in earlier nano-LC MS experiments
using gradient elution conditions (see also above) some-
times a shift in retention time of the reference com-
pounds was noted (sometimes up to 1 min) no real
distinction between diastereomers dC3 and dC4 could
be made because the tR of both compounds differed by
only 1.4 min. In Figures 3 and 4, the upper traces show
the SRM transition 548  432 and 564  448 of dA and
dG standards. In the lower trace the response of the breast
tumor tissue of patient 4 (Figure 3) and patient 13 (Figure
4) is given. In the tumor sample signals could be seen at a
retention time of 42, 2, and 37.3 min, respectively. This
Figure 1. Chromatogram of SRM channel 554 438 (estradiol-2'-deoxy guanosine adduct) of a breast
tumor DNA (patient 3) analyzed with nano LC-nano ()ES MS (picofrit column 75 m  10 cm,
Aquasyl C18) with column switching (300 m  5mm, C18, 10 m) after 12 min, 100 L injection
volume (ca. 38 g DNA).
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corresponded exactly with the same retention time as the
dA3 and dG4 reference adduct. Remarkebly, 4OHEN
adducts were found in either tumorous or healthy tissue,
but never in the both tissues at the same time.
Patients 5, 7, and 8 received Premarin (equilenin) but
no adducts were detected. However, in these cases the
amount of tissue was extremely small (smallest sample
was 0.2 cm3) which could explain that even under SRM
conditions no conclusions could be drawn. As far as we
know patient 6 did not receive Premarin, nevertheless
an equilenin adduct was found. At the moment no
plausible explanation for this observation can be given
unless the medical background of the patient was
incomplete. Such uncertainties should be avoided in the
future by implementing a good protocol with regard to
the patient’s history.
In many of the samples, adducts of 4-hydroxy-17--
ethynylestradiol were detected such as adducts of dAdo
(patients 3, 6 –11), dGuo (patients 10, 11, 13) and
thymidine (patients 7, 8, 12, 13). This is not entirely
surprising because of its use as a contraceptive.
Figure 5 shows the detection of a standard of a
dAdo-4-hydroxy-17--ethynyl-estradiol adduct in
the upper trace and the corresponding SRM transi-
Figure 2. Chromatogram of SRM channel 538  432 (equilenin-2'-deoxy adenosine adduct). Upper:
In vitro prepared reference adducts. Lower: Breast tumor DNA of patient 9 treated with equilenin.
Both were analyzed with nano LC-nano ()ES MS (picofrit column 75 m  10 cm, aquasyl C18) with
column switching (300 m  5 mm, C18, 10 m) after 12 min, 100 L injection volume ( 38 g DNA).
The peak at 18.18 min is not an adduct; it is a component that is even present in a blank injection.
Figure 3. Chromatogram of SRM trace 548  432 (equilenin-2'-deoxy adenosine adduct). Upper: In
vitro prepared reference adducts. Lower: Breast tumor DNA of patient 4 treated with equilenin. Both
were analyzed with nano LC-nano ()ES MS (Column 75 m  15 cm, BDS C8) with column switching
(300 m  5 mm, C18P3, 10 m) after 7 min, 20 L injection volume ( 7.6 g DNA).
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tion found in a breast tumor sample in the lower
trace. The specific SRM transition, together with the
comparable retention time as the synthesized stan-
dard, again identified the adduct in the breast tumor
sample.
Finally, it is worthwhile mentioning that in some
samples an adduct was present responding to the 570
454 SRM transition. This response was indicative for the
presence (patients 1–3, 7) of a dGuo adduct of benzo-
[a]pyrene 7,8-diol 9,10-epoxide. This adduct eluted ap-
proximately 3 min after the last eluting equilenin refer-
ence adduct, depending on the solvent system used.
At the moment no quantitative measurements
have been taken, but a rough estimation can be made
on the basis of the detection limit of 200 fg for a
4OHEN-dGuo adduct [33]. In most of the 2-DLC-MS
runs around 38 g of DNA (hydrolysate) was in-
jected. This means that 2.8 adducts in 109 nucleosides
were detected. Since the signal of most DNA-adducts
detected here was close to the detection limit, we may
Figure 4. Chromatogram of SRM trace 564  448 (equilenin-2'-deoxy guanosine adduct). Upper: In
vitro prepared reference adducts. Lower: Breast tumor DNA of patient 13 treated with equilenin
(Premarin). Both were analyzed with nano LC-nano ()ES MS (picofrit column 75 m  10 cm, aquasyl
C18) with column switching (300 m  5 mm, C18, 10 m) after 12 min, 100 L injection volume (
38 g DNA).
Figure 5. Chromatogram of SRM trace 562 446 (17--ethynylestradiol-2'-deoxy adenosine adduct).
Upper: In vitro prepared reference adducts. Lower: Breast tumor DNA of patient 3 treated with
equilenin. Both were analyzed with nano LC-nano ()ES MS (picofrit column 75 m  10 cm, aquasyl
C18) with column switching (300 m  5 mm, C18, 10 m) after 12 min, 100 L injection volume (
38 g DNA).
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assume the estrogen DNA-adducts to be present in
the same order of magnitude.
Conclusion
From the data presented above we can conclude that
nano-LC coupled to nano-electrospray tandem mass
spectrometry can be used for DNA-adduct analysis in
human DNA. Adducts of endogenous and exogenous
estrogens like equilenin, which is proven to be carcino-
genic [7, 8], could be found in breast-tumor tissue and
adjacent normal breast tissue. However we hereby want
to stress that these results are very preliminary and that
in order to (1) validate the complete procedure and (2)
draw biochemical conclusions it is obvious that many
more samples need to be analyzed, quantitative data
included, and a tight protocol covering the patient’s
medical history should be designed. Furthermore, a
careful selection of blank tissue will be important for
future measurements.
Acknowledgments
The authors gratefully acknowledge the Fund for Scientific Re-
search Vlaanderen (grants G.2133.94.N, G0334.00, and 1.5.139.00)
and the Flemish Government (GOA-action) for financial support.
JE thanks IWT for a research grant. Furthermore, the authors
thank Jef Thielemans for kindly preparing the paraffin embedded
material sections.
References
1. Lobo, R. A. Benefits and Risks of Estrogen Replacement
Therapy. Am. J. Obstet. Gynecol. 1995, 173, 982–1003.
2. Feigelson, H. S.; Henderson, B. E. Estrogens and Breast Can-
cer. Carcinogenesis 1996, 17, 2279–2284.
3. Brinton, L. A.; Hoover, R.; Fraumeni, J. F., Jr. Menopausal
Estrogens and Breast Cancer Risk: An Expanded Case-Control
Study. Br. J. Cancer. 1986, 54, 825–832.
4. Henderson, B. E.; Ross, R. K.; Bernstein, L. Estrogens as a
Cause of Human Cancer. Cancer Res. 1988, 48, 246–253.
5. Persson, I.; Yuen, J.; Bergkvist, L.; Schairer, C. Cancer Inci-
dence and Mortality in Women Receiving Estrogen and Estro-
gen-Progestin Replacement Therapy—Long-Term Follow-Up
of a Swedish Cohort C. Int. J. Cancer. 1996, 67, 327–332.
6. Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.;
Manson, J. E.; Stampfer, M. J.; Hennekens, C.; Rosner, B.;
Speizer, F. E. The Use of Estrogens and Progestins and the
Risk of Breast Cancer in Postmenopausal Women. New Eng.
J. Med. 1995, 332, 1589–1593.
7. Schairer, C.; Lubin, J.; Troisi, R.; Sturgeon, S.; Brinton, L.;
Hoover, R. Menopausal Estrogen and Estrogen-Progestin Re-
placement Therapy and Breast Cancer Risk. J. Am. Med. Assoc.
2000, 4, 485–491.
8. Li, J. J.; Li, S. A.; Oberley, T. D.; Parson, J. A. Carcinogenic
Activities of Various Steroidal and Nonsteroidal Estrogens in
the Hamster Kidney: Relation to Hormonal Activity and Cell
Proliferation. Cancer Res. 1995, 55, 4347–4351.
9. Zhu, B. T.; Roy, D.; Liehr, J. G. The Carcinogenic Activity of
Ethynyl Estrogens is Determined by Both Their Hormonal
Characteristics and Their Conversion to Catechol Metabolites.
Endocrinology 1993, 132, 577.
10. Nandi, S.; Guzman, R. C.; Yang, J. Hormones and Mammary
Carcinogenesis in Mice, Rats, and Humans—a Unifying Hy-
pothesis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3650–3657.
11. Liehr, J. G.; Stancel, G. M.; Chorich, L. P.; Bousfield, G. R.;
Ulubelen, A. A. Hormonal Carcinogenesis—Separation of
Estrogenicity from Carcinogenicity. Chem. Biol. Interact. 1986,
59, 173–184.
12. Liehr, J. G.; Purdy, R. H.; Baran, J. S.; Nutting, E. F.; Colton, F.;
Randerath, E.; Randerath, K. Correlation of Aromatic Hy-
droxylation of 11--Substituted Estrogens with Morphological
Transformation in Vitro but not with in Vivo Tumor Induction
by These Hormones. Cancer Res. 1987, 47, 2583–2588.
13. Zhu, B. T.; Conney, A. Functional Role of Estrogen Metabo-
lism in Target Cells: Review and Perspectives. Carcinogenesis
1998, 19, 1.
14. Bradlow, H. L.; Telang, N. T.; Sopkovic, D. W.; Osborn, M. P.
2-Hydroxyestrone: The “good” Estrogen. J. Endocrinol. 1996,
150, S259.
15. Bolton, J. L.; Pisha, E.; Zhang, F.; Qiu, S. INVITED REVIEW:
Role of Quinoids in Estrogen Carcinogenesis. Chem. Res.
Toxicol. 1998, 11, 1113–1127.
16. Mobley, J. A.; Bhat, A. S.; Brueggemeier, R. W. Measurement
of Oxidative DNA Damage by Catechol Estrogens and Ana-
logues in Vitro. Chem. Res. Toxicol. 1999, 12(3), 270–277.
17. Shen, L.; Pisha, E.; Huang, Z.; Pezzuto, J. M.; Krol, E.; Alam, Z.;
Van Breemen, R. B.; Bolton, J. L. Bioreductive Activation of
Catechol Estrogen-Ortho-Quinones: Aromatization of the B
Ring in 4-Hydroxyequilenin Markedly Alters Quinoid Forma-
tion and Reactivity. Carcinogenisis 1997, 18, 1093–1101.
18. Zhang, F.; Chen, Y.; Pisha, E.; Shen, L.; Xiong, Y.; Van
Breemen, R. B.; Bolton, J. L. The Major Metabolite of Equilin,
4-Hydroxyequilin, Autoxidizes to an o-Quinone which
Isomerizes to the Potent Cytotoxin 4-Hydroxyequilenin-o-
Quinone. Chem. Res. Toxicol. 1999, 12, 204–213.
19. Shen, L.; Qiu, S.; Chen, Y.; Zhang, F.; Van Breemen, R. B.;
Nikolic, D.; Bolton, J. L. Alkylation of 2'-Deoxynucleosides and
DNA by the Premarin Metabolite 4-Hydroxyequilenin
Semiquinone Radical. Chem. Res. Toxicol. 1998, 11, 94–101.
20. Akanni, A.; Tabacovic, K.; Abul-Hajj, Y. J. Estrogen-Nucleic
Acid Adducts: Reaction of 3,4-Estrone o-Quinone with Nu-
cleic Acid Bases. Chem. Res. Toxicol. 1997, 10, 477–481.
21. Van Aerden, C.; Debrauwer, L.; Tabet, J. C.; Paris, A. Analysis
of Nucleoside-Estrogen Adducts by LC-ESI-MS-MS. Analyst
1998, 123, 2677–2680.
22. Devanesan, P.; Todorvic, R.; Zhao, J.; Gross, M. L.; Rogan,
E. G.; Cavalieri, E. L. Catechol Estrogen Conjugates and DNA
in the Kidney of Male Syrian Golden Hamsters Treated with
4-Hydroxy-Estradiol: Potential Biomarkers for Estrogen-Initi-
ated Cancer. Carcinogenesis 2001, 22(3), 489–497.
23. Todorvic, R.; Devanesan, P.; Higginbotham, S.; Zhao, J.; Gross,
M. L.; Rogan, E. G.; Cavalieri, E. L. Analysis of Potential
Biomarkers of Estrogen-Initiated Cancer in the Urine of Syrian
Golden Hamsters Treated with 4-Hydroxy-Estradiol. Carcino-
genesis 2001, 22(6), 905–911.
24. Cavalieri, E. L.; Stack, D. E.; Devanesan, P. D.; Todorvic, R.;
Dwivedy, I.; Higginbotham, S.; Johansson, S. L.; Patil, K. D.;
Gross, M. L.; Gooden, J. K.; Ramanathan, R.; Cerny, R. L.;
Rogan, E. G. Molecular Origin of Cancer: Catechol Estrogen-
3,4-Quinones as Endogenous Tumor Initiators. Proc. Natl.
Acad. Sci. U.S.A. 1997, 94(20), 10937–10942.
25. Cavalieri, E. L.; Kumar, S.; Todorvic, R.; Higginbotham, S.;
Badawi, A. F.; Rogan, E. G. Imbalance of Estrogen Homeosta-
sis in Kidney and Liver of Hamsters Treated with Estradiol:
Implications for Estrogen-Induced Initiations of Renal Tu-
mors. Chem. Res. Toxicol. 2001, 14(8), 1041–1050.
26. Stack, D.; Byun, J.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L.
Molecular Characteristics of Catechol Estrogen Quinones in
490 EMBRECHTS ET AL. J Am Soc Mass Spectrom 2003, 14, 482–491
Reaction with Deoxyribonucleosides. Chem. Res. Toxicol. 1996,
9, 851–859.
27. Jan, S.-T.; Devanesan, P. D.; Stack, D.; Ramanathan, R.; Byun,
J.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L. Metabolic
Activation and Formation of DNA Adducts of Hexestrol, a
Synthetic Nonsteroidal Carcinogenic Estrogen. Chem. Res.
Toxicol. 1998, 11, 412–419.
28. Liehr, J. G. Genotoxic Effects of Estrogens. Mutat. Res. 1990,
238, 269–276.
29. Chakravarti, D.; Mailander, P. C.; Li, K. M.; Higginbotham, S.;
Zhang, H. L.; Gross, M. L.; Meza, J. L.; Cavalieri, E. L.; Rogan,
E. G. Evidence That a Burst of DNA Depurination in SENCAR
Mouse Skin Induces Error-Prone Repair and Forms Mutations
in the H-ras Gene. Oncogene 2001, 20(55), 7945–7953.
30. Shen, L.; Qiu, S.; Van Breemen, R. B.; Zhang, F.; Chen, Y.;
Bolton, J. L. Reaction of the Premarin Metabolite 4-Hy-
droxyequilemn Semiquinone Radical with 2'-Deox-
yguanosine: Formation of Unusual Cyclic Adducts. J. Am.
Chem. Soc. 1997, 119, 11126–11127.
31. Li, D.; Wang, M. Y.; Dhingra, K.; Hittelman, W. N. Aromatic
DNA Adducts in Adjacent Tissues of Breast Cancer Patients:
Clues to Breast Cancer Etiology. Cancer Res. 1996, 56, 287–293.
32. Li, D.; Wang, M. Y.; Firozi, P. F.; Chan, P.; Zhang, W.;
Baer-Dubowska, W.; Moorthy, B.; Vulirimi, S. V.; Goth-Gold-
stein, R.; Weyand, A. H.; DiGiovanni, J. Characterization of a
Major Aromatic DNA Adduct Detected in Human Breast
Tissues. Environ. Mol. Mutagen. 2002, 39, 193–200.
33. Embrechts, J.; Lemie`re, F.; Van Dongen, W.; Esmans, E. L.
Equilenin-2'-Deoxynucleoside Adducts: Analysis with Nano-
Liquid Chromatography Coupled to Nano-Electrospray Tan-
dem Mass Spectrometry. J. Mass Spectrom. 2001, 36, 317–328.
34. Crain, P. M. Preparation and Enzymatic Hydrolysis of DNA
and RNA for Mass Spectrometry. Methods in Enzymology 193;
In: McCloskey, J. A., Ed.; Academic Press, Inc: San Diego,
1990; pp 782–790.
35. Zhang, F.; Swanson, S. M.; Van Breemen, R. B.; Liu, X. M.;
Yang, Y. N.; Gu, C. G.; Bolton, J. L. Equine Estrogen Metabolite
4-Hydroxyequilenin Induces DNA Damage in the Rat Mam-
mary Tissues: Formation of Single-Strand Breaks, Apurinic
Sites, Stable Adducts, and Oxidized Bases. Chem. Res. Toxicol.
2001, 14, 1654–1659.
36. Paehler, A.; Richoz, J.; Soglia, J.; Vouros, P.; Turesky, R. J.
Analysis and Quantification of DNA Adducts of 2-Amino-3,8-
Dimethylimidazo(4,5-f)Quinoxaline in Liver of Rats by Liquid
Chromatography/Electrospray Tandem Mass Spectrometry.
Chem. Res. Toxicol. 2002, 15, 551–561.
37. Hasan K., Swenberg J. A.Applications of Mass Spectrometry
for Quantitations of DNA Adducts. J. Chromatog. B, in press,
and references cited therein.
38. Richardson, F. C.; Zhang, C. H.; Lehrman, S. R.; Koc, H.;
Swenberg, J. A.; Richardson, K. A.; Bendele, R. A. Quantifica-
tion of 2 '-Fluoro-2'-Deoxyuridine and 2'-Fluoro-2'-Deoxycyti-
dine in DNA and RNA Isolated from Rats and Woodchucks
Using LC/MS/MS. Chem. Res. Toxicol. 2002, 15(7), 922–926.
39. Chaudhary, A. K.; Reddy, G. R.; Blair, I. A.; Marnett, L. J.
Characterization of an N-6-Oxopropenyl-2'-Deoxyadenosine
Adduct in Malondialdehyde-Modified DNA Using Liquid.
Carcinogenesis 1996, 17(5), 1167–1170.
40. Doerge, D. R.; Churchwell, M. I.; Fang, J. L.; Beland, F. A.
Quantification of Etheno-DNA Adducts Using Liquid Chro-
matography, On-Line Sample Processing, and Electrospray
Tandem Mass Spectrometry. Chem. Res. Toxicol. 2000, 13(12),
1259–1264.
41. Zhang, F.; Swanson, S. M.; van Breemen, R. B.; Liu, X. M.;
Yang, Y. N.; Gu, C. G.; Bolton, J. L. Equine Estrogen Metabolite
4-Hydroxyequilenin Induces DNA Damage in the Rat Mam-
mary Tissues: Formation of Single-Strand Breaks, Apurinic
Sites, Stable Adducts, and Oxidized Bases. Chem. Res. Toxicol.
2001, 14(12), 1654–1659.
42. Vanhoutte, K.; Van Dongen, W.; Hoes, I.; Lemiere, F.; Esmans,
E. L.; Van Onckelen, H.; Van Den Eeckhout, E.; Van Soest,
R. E. J.; Hudson, A. J. Development of a Nanoscale Liquid
Chromatography/Electrospray Mass Spectrometry Methodol-
ogy for the Detection and Identification of DNA Adducts.
Anal. Chem. 1997, 69, 3161–3168.
43. Vanhoutte, K.; Joos, P.; Lemiere, F.; Van Dongen, W.; Esmans,
E. L. Thermospray Liquid Chromatography-Mass Spectro-
metry of the DNA Adducts Formed Between 2'-Deoxynucleo-
sides and Bisphenol A Diglycidyl Ether. J. Mass Spectrom. 1995,
XXX, S143–S152 special volume.
44. Hoes, I.; Lemiere, F.; Van Dongen, W.; Vanhoutte, K.; Esmans,
E. L.; Van Bockstaele, D.; Berneman, Z.; Deforce, D.; Van den
Eeckhout, E. G. Analysis of Melphalan Adducts of 2'-De-
oxynucleotides in Calf Thymus DNA Hydrolysates by Capil-
lary High-Performance Liquid Chromatography-Electrospray
Tandem Mass Spectrometry. J. Chromatog. B 1999, 736, 43–59.
45. Hoes, I.; Van Dongen, W.; Lemie`re, F.; Esmans, E. L.; Van
Bockstaele, D.; Berneman, Z. N. Comparison Between Capil-
lary and Nano Liquid Chromatography-Eelectrospray Mass
Spectrometry for the Analysis of Minor DNA-Melphalan
Adducts. J. Chromatog. B 2000, 748, 197–212.
46. Rindgen, D.; Turesky, R. J.; Vouros, P. Determination of in
Vitro Formed DNA Adducts of 2-Amino-1-Methyl-6-Pheny-
limidazo(4,5-b)Pyridine Using Capillary Liquid Chromatogra-
phy/Electrospray Ionization/Tandem Mass Spectrometry.
Chem. Res. Toxicol. 1995, 8, 1005–1013.
47. Wolf, S. M.; Vouros, P. Application of Capillary Liquid Chro-
matography Coupled with Tandem Mass Spectrometric Meth-
ods to the Rapid Screening of Adducts Formed by the Reac-
tion of N-Acetoxy-N-Acetyl-2-Aminofluorene with Calf
Thymus DNA. Chem. Res. Toxicol. 1994, 7, 82–88.
48. Gangl, E. T.; Turesky, R. J.; Vouros, P. Determination of in
Vitro and in Vivo Formed DNA Adducts of 2-Amino-3-
Methylimidazo[4,5-f]Quinoline by Capillary Liquid Chroma-
tography/Microelectrospray Mass Spectrometry. Chem. Res.
Toxicol. 1999, 12, 1019–1027.
49. Siethoff, C.; Linscheid, M.Proceedings of the 45th ASMS Confer-
ence on Mass Spectrometry and Allied Topics; Palm Springs,
California, June 1–5, 1997; p 290.
50. Barry, J. P.; Norwood, C.; Vouros, P. Detection and Identifi-
cation of Benzo[a]Pyrene Diol Adducts to DNA Utilizing
Capillary Electrophoresis-Electrospray Mass Spectrometry.
Anal. Chem. 1996, 68, 1432–1438.
51. Convert O., Van Aerden C., Debrauwer L., Rathatao E.,
Molines H., Fournier F., Tabet J., Paris A. Reactions of Estra-
diol-2,3-Quinone with Deoxyribonucleosides: Possible In-
sights in the Reactivity of Estrogen Quinines with DNA. Chem.
Res. Toxicol., in press.
52. Vanhoutte, K.; Van Dongen, W.; Esmans, E. L.; Van den
Eeckhout, E.; Van Onkelen, H. A Strategy for the Identification
of 2'-Deoxynucleoside and 2'-Deoxynucleosite Adducts Using
Electrospray Tandem Mass Spectrometry. Eur. Mass Spectrom.
1996, 2, 181–192.
491J Am Soc Mass Spectrom 2003, 14, 482–491 LC-MS OF ESTROGEN DNA-ADDUCTS IN BREAST TISSUE
